This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dercamp, C. Articles by Vicari, A. P. Search for Related Content PubMed PubMed Citation Articles by Dercamp, C. Articles by Vicari, A. P.

Distinct and Overlapping Roles of Interleukin-10 and CD25⁺ Regulatory T Cells in the Inhibition of Antitumor CD8 T-Cell Responses

Laboratory for Immunological Research, Schering-Plough Research Institute, Dardilly, France

Requests for reprints: Christophe Dercamp, Institut National de la Sante et de la Recherche Medicale U404, 21 Avenue Tony Garnier, 69365 Lyon Cedex 07, France. Phone: 33-4-37-28-23-98; Fax: 33-4-37-28-23-91; E-mail: dercamp{at}cervi-lyon.inserm.fr.

Lack of antitumor immunity is often related to impaired CD8 T-cell responses that could result from a poor priming capacity by tumor-infiltrating dendritic cells (TIDC) and/or further inhibition by regulatory T cells (T_reg). Interleukin-10 (IL-10) has been implicated in the inhibition of TIDC as well as in the generation and functions of T_reg. Here, we address some of the respective and possibly overlapping roles of IL-10 and CD25⁺ T_reg in CD8 antitumor immunity. Whereas tumor antigen–specific CD8 T cells proliferated in vivo in the presence of IL-10 or T_reg, optimal effector functions were observed in mice lacking both IL-10 and T_reg. Indeed, tumors grown in normal but not in IL-10–deficient or CD25-depleted mice induced tumor antigen–specific CD8 suppressor T cells. Suppression involved transforming growth factor-ß. Similarly, both IL-10 and T_reg were responsible for impaired CD8 T cell priming by TIDCs, but IL-12 production by TIDCs was prevented only by T_reg-independent IL-10. Subsequently, IL-10 defect and T_reg depletion were required to achieve optimal induction of CD8 T-cell effectors by TIDC following CpG activation. Our results point out major redundant and nonredundant roles for IL-10 and T_reg in the inhibition of TIDC-mediated generation of antitumor CD8 T-cell response.

This article has been cited by other articles:

				W. Wang, R. Lau, D. Yu, W. Zhu, A. Korman, and J. Weber PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells Int. Immunol., September 1, 2009; 21(9): 1065 - 1077. [Abstract] [Full Text] [PDF]

				A. K. Bauer and E. A. Rondini REVIEW PAPER: The Role of Inflammation in Mouse Pulmonary Neoplasia Vet. Pathol., May 1, 2009; 46(3): 369 - 390. [Abstract] [Full Text] [PDF]

				M. Ahmadi, D. C. Emery, and D. J. Morgan Prevention of Both Direct and Cross-Priming of Antitumor CD8+ T-Cell Responses following Overproduction of Prostaglandin E2 by Tumor Cells In vivo Cancer Res., September 15, 2008; 68(18): 7520 - 7529. [Abstract] [Full Text] [PDF]

				D. Chiron, I. Bekeredjian-Ding, C. Pellat-Deceunynck, R. Bataille, and G. Jego Toll-like receptors: lessons to learn from normal and malignant human B cells Blood, September 15, 2008; 112(6): 2205 - 2213. [Abstract] [Full Text] [PDF]

				S. Piconese, B. Valzasina, and M. P. Colombo OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection J. Exp. Med., April 14, 2008; 205(4): 825 - 839. [Abstract] [Full Text] [PDF]

				S. Yotsumoto, K. Saegusa, and Y. Aramaki Endosomal Translocation of CpG-Oligodeoxynucleotides Inhibits DNA-PKcs-Dependent IL-10 Production in Macrophages J. Immunol., January 15, 2008; 180(2): 809 - 816. [Abstract] [Full Text] [PDF]

				P. Zhou, L. L'italien, D. Hodges, and X. M. Schebye Pivotal Roles of CD4+ Effector T cells in Mediating Agonistic Anti-GITR mAb-Induced-Immune Activation and Tumor Immunity in CT26 Tumors J. Immunol., December 1, 2007; 179(11): 7365 - 7375. [Abstract] [Full Text] [PDF]

				V. Andreani, G. Gatti, L. Simonella, V. Rivero, and M. Maccioni Activation of Toll-like Receptor 4 on Tumor Cells In vitro Inhibits Subsequent Tumor Growth In vivo Cancer Res., November 1, 2007; 67(21): 10519 - 10527. [Abstract] [Full Text] [PDF]

				Y.-X. Chen, K. Man, G. S. Ling, Y. Chen, B.-S. Sun, Q. Cheng, O. H. Wong, C.-K. Lo, I. O.-L. Ng, L. C. Chan, et al. A Crucial Role for Dendritic Cell (DC) IL-10 in Inhibiting Successful DC-Based Immunotherapy: Superior Antitumor Immunity against Hepatocellular Carcinoma Evoked by DC Devoid of IL-10 J. Immunol., November 1, 2007; 179(9): 6009 - 6015. [Abstract] [Full Text] [PDF]

				M. J. Dobrzanski, J. B. Reome, J. C. Hylind, and K. A. Rewers-Felkins CD8-Mediated Type 1 Antitumor Responses Selectively Modulate Endogenous Differentiated and Nondifferentiated T Cell Localization, Activation, and Function in Progressive Breast Cancer J. Immunol., December 1, 2006; 177(11): 8191 - 8201. [Abstract] [Full Text] [PDF]